A review of mathematical models of influenza A infections within a host or cell culture: Lessons learned and challenges ahead

BMC Public Health

Volumn 11, Issue SUPPL. 1, 2011, Pages

  Beauchemin, Catherine A A ^a   Handel, Andreas ^b  

^a RYERSON UNIVERSITY   (Canada)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOLOGICAL MODEL; CULTURE TECHNIQUE; DISEASE TRANSMISSION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; PATHOGENICITY; PHYSIOLOGY; THEORETICAL MODEL; VIRUS REPLICATION;

CELL CULTURE TECHNIQUES; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; MODELS, THEORETICAL; VIRUS REPLICATION;

EID: 79952567961     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-S1-S7     Document Type: Review

References (130)

1. Nicholson KG, Wood JM, Zambon M: Influenza. The Lancet 2003, 362:1733-1745. (Pubitemid 37468326)
2. World Health Organization: Influenza. Fact Sheet 211, World Health Organization Revised; 2009 [http://www.who.int/mediacentre/factsheets/fs211/].
3. Cheung TKW, Poon LLM: Biology of influenza A virus. Ann. N.Y. Acad. Sci. 2007, 1102:1-25.
4. Sweet C, Smith H: Pathogenicity of influenza virus. Microbiol Rev 1980, 44(2):303-330. (Pubitemid 11128311)
5. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T: H5N1 virus attachment to lower respiratory tract. Science 2006, 312(5772):399, Originally published in Science Express on 23 March 2006.
6. Nicholls J, Chan M, Chan W, Wong H, Cheung C, Kwong D, Wong M, Chui W, Poon LLM, Tsao S, Guan Y, Peiris J: Tropism of avian influenza A H5N1 in the upper and lower respiratory tract. Nature Medicine 2007, 13(2):147-149.
7. Potter CW: Influenza. In Principles and Practice of Clinical Virology Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD, John Wiley & Sons, Ltd. , 5th 2004, 271-297.
8. Patton JS: Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliver. Rev. 1996, 19:3-36.
9. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD: Human and avian influenza viruses target different cell types in cultures of human airway epithelium. P. Natl. Acad. Sci. USA 2004, 101(13):4620-4624.
10. Matrosovich MN, Matrosovich TY, Uhlendorff J, Garten W, Klenk HD: Avian-virus-like receptor specificity of the hemagglutinin impedes influenza virus replication in cultures of human airway epithelium. Virology 2007, 361(2):384-390. (Pubitemid 46574852)
11. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y: Influenza virus receptors in the human airway. Nature 2006, 440(7083):435-436.
12. Davenport FM: Pathogenesis of influenza. Bacteriol Rev 1961, 25:294-300.
13. Mora R, Rodriguez-Boulan E, Palese P, Garía-Sastre A: Apical budding of a recombinant influenza A virus expressing a hemagglutinin protein with a basolateral localization signal. J. Virol. 2002, 76(7):3544-3553. (Pubitemid 34224555)
14. Tamura S, Kurata T: Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn. J. Infect. Dis. 2004, 57(6):236-247.
15. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS: Kinetics of influenza A virus infection in humans. J. Virol. 2006, 80(15):7590-7599. (Pubitemid 44092580)
16. Basler CF, Aguilar PV: Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses. Antiviral Res. 2008, 79(3):166-178.
17. Guarner J, Falcón-Escobedo R: Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses. Arch Med Res 2009, 40(8):655-661.
18. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS: Strategies for mitigating an influenza pandemic. Nature 2006, 442(7101):448-452. (Pubitemid 44264793)
19. Germann TC, Kadau K, Longini IM, Macken CA: Mitigation strategies for pandemic influenza in the United States. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(15):5935-5940.
20. Halloran ME, Ferguson NM, Eubank S, Longini IM, Cummings DAT, Lewis B, Xu S, Fraser C, Vullikanti A, Germann TC, Wagener D, Beckman R, Kadau K, Barrett C, Macken CA, Burke DS, Cooley P: Modeling targeted layered containment of an influenza pandemic in the United States. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(12):4639-4644.
21. McVernon J, McCaw CT, Mathews JD: Model answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planning. Influenza Other Respi Viruses 2007, 1(2):43-54.
22. Hatchett RJ, Mecher CE, Lipsitch M: Public health interventions and epidemic intensity during the 1918 influenza pandemic. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(18):7582-7587.
23. Kim SY, Goldie SJ: Cost-effectiveness analyses of vaccination programmes: A focused review of modelling approaches. Pharmacoeconomics 2008, 26(3):191-215.
24. Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S: Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med. 2009, 6(5):e1000085.
25. Coburn BJ, Wagner BG, Blower S: Modeling influenza epidemics and pandemics: Insights into the future of swine flu (H1N1). BMC Med 2009, 7:30.
26. Kerkhove MDV, Asikainen T, Becker NG, Bjorge S, Desenclos JC, dos Santos T, Fraser C, Leung GM, Lipsitch M, Longini IM, McBryde ES, Roth CE, Shay DK, Smith DJ, Wallinga J, White PJ, Ferguson NM, Riley S, W H O Informal Network for Mathematical Modelling for Pandemic Influenza H1N1 2009 (WorkingGroup on Data Needs): Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. PLoS Med. 2010, 7(6):e1000275.
27. Smith AM, Ribeiro RM: Modeling the viral dynamics of influenza A virus infection. Crit. Rev. Immunol. 2010, 30(3):291-298.
28. Lloyd AL: The dependence of viral parameter estimates on the assumed viral life cycle: Limitations of studies of viral load data. Proc Biol Sci 2001, 268(1469):847-854.
29. Wearing HJ, Rohani P, Keeling MJ: Appropriate models for the management of infectious diseases. PLoS Med 2005, 2(7):e174.
30. Holder BP, Beauchemin CAA: Exploring the effect of implementing different biological delays in constructing kinetic models of influenza infection within a host or cell culture. BMC Public Health 2011, 11((Suppl 1)):S10, submitted.
31. Miao H, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR, Perelson AS, Wu H, Topham DJ: Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J. Virol. 2010, 84(13):6687-6698.
32. Doherty PC, Turner SJ, Webby RG, Thomas PG: Influenza and the challenge for immunology. Nature Immunol. 2006, 7(5):449-455.
33. Larson E, Dominik J, Rowberg A, Higbee G: Influenza virus population dynamics in the respiratory tract of experimentally infected mice. Infect. Immun. 1976, 13(2):438-447.
34. Perelson AS, Neumann A, Markowitz M, Leonard J, Ho D: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271(5255):1582-1586. (Pubitemid 26097216)
35. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD: Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997, 387(6629):188-191. (Pubitemid 27209434)
36. Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS: Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003, 38(2):509-517. (Pubitemid 36919873)
37. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282(5386):103-107. (Pubitemid 28471138)
38. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ: Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 2000, 182:28-35.
39. Handel A, Longini IM, Antia R: Neuraminidase inhibitor resistance in influenza: Assessing the danger of its generation and spread. PLoS Comput. Biol. 2007, 3(12):e240.
40. Dobrovolny HM, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA: Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative study. J. Theor. Biol. 2011, 269(1):234-244, submitted.
41. Baron MJ, Dobrovolny HM, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA: Exploring cell tropism as a possible contributor to influenza infection severity. PLoS ONE 2010, 5(11):e13811, submitted.
42. Möhler L, Flockerzi D, Sann H, Reichl U: Mathematical model of influenza A virus production in large-scale microcarrier culture. Biotechnol. Bioeng. 2005, 90:46-58.
43. Sidorenko Y, Voigt A, Schulze-Horsel J, Reichl U, Kienle A: Stochastic population balance modeling of influenza virus replication in vaccine production processes. II. Detailed description of the replication mechanism. Chem. Eng. Sci. 2008, 63(8):2299-2304.
44. Sidorenko Y, Schulze-Horsel J, Voigt A, Reichl U, Kienle A: Stochastic population balance modeling of influenza virus replication in vaccine production processes. Chem. Eng. Sci. 2008, 63:157-169.
45. Schulze-Horsel J, Schulze M, Agalaridis G, Genzel Y, Reichl U: Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production - Flow cytometry and mathematical modeling. Vaccine 2009, 27(20):2712-2722.
46. Sidorenko Y, Reichl U: Structured model of influenza virus replication in MDCK cells. Biotechnol Bioeng 2004, 88:1-14. (Pubitemid 39388688)
47. Beauchemin CA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, Ribeiro RM, Perelson AS: Modeling amantadine treatment of influenza A virus in vitro. J. Theor. Biol. 2008, 254(2):439-451.
48. Holder BP, Simon P, Liao LE, Abed Y, Bouhy X, Beauchemin CAA, Boivin G: Assessing fitness of an oseltamivir-resistant seasonal A/H1N1 influenza strain using a mathematical model. PLoS ONE 2011, accepted.
49. Holder BP, Liao LE, Simon P, Boivin G, Beauchemin CAA: Design considerations in building in silico equivalents of common experimental influenza virus assays and the benefits of such an approach. Autoimmunity 2011, 44(4), in press.
50. Francis T, Stuart-Harris CH: Studies on the nasal histology of epidemic influenza virus infection in the ferret I. The development and repair of the nasal lesion. J. Exp. Med. 1938, 68(6):789-U7.
51. Stuart-Harris CH: Maxwell Finland lecture: The influenza viruses and the human respiratory tract. Rev Infect Dis 1979, 1(4):592-599.
52. Rocha E, Cox NJ, Black RA, Harmon MW, Harrison CJ, Kendal AP: Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child. J. Virol. 1991, 65(5):2340-2350.
53. Boivin G, Goyette N, Bernatchez H: Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin. Infect. Dis. 2002, 34(5):E23-E25.
54. Weinstock DM, Gubareva LV, Zuccotti G: Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med. 2003, 348(9):867-868.
55. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ: Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J. Infect. Dis. 1995, 172(5):1352-1355.
56. Glies C, Shuttleworth EM: Postmortem findings in 46 influenza deaths. Lancet 1957, 273(7007):1224-1225.
57. Hers JF, Masurel N, Mulder J: Bacteriology and histopathology of the respiratory tract and lungs in fatal Asian influenza. Lancet 1958, 2(7057):1141-1143.
58. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, van Vinh Chau Nguyen, Pham TS, Vo CD, Le TQM, Ngo TT, Dao BK, Le PP, Nguyen TT, Hoang TL, Cao VT, Le TG, Nguyen DT, Le HN, Nguyen KT, Le HS, Le VT, Christiane D, Tran TT, de Jong Menno, Schultsz C, Cheng P, Lim W, Horby P, Farrar J, World Health Organization International Avian Influenza Investigative Team: Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 2004, 350(12):1179-1188.
59. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, Chau TNB, Hoang DM, Chau NVV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha DQ, Guan Y, Peiris JSM, Chinh NT, Hien TT, Farrar J: Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 2006, 12(10):1203-1207.
60. Morens DM, Fauci AS: The 1918 influenza pandemic: Insights for the 21st century. J. Infect. Dis. 2007, 195(7):1018-1028.
61. Morens DM, Taubenberger JK, Fauci AS: Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness. J. Infect. Dis. 2008, 198(7):962-970.
62. La Gruta NL, Kedzierska K, Stambas J, Doherty PC: A question of self-preservation: Immunopathology in influenza virus infection. Immunol Cell Biol 2007, 85(2):85-92. (Pubitemid 46398724)
63. Szretter KJ, Gangappa S, Lu X, Smith C, Shieh WJ, Zaki SR, Sambhara S, Tumpey TM, Katz JM: Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J. Virol. 2007, 81(6):2736-2744. (Pubitemid 46447038)
64. Salomon R, Hoffmann E, Webster RG: Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(30):12479-12481.
65. Peiris JSM, Cheung CY, Leung CYH, Nicholls JM: Innate immune responses to influenza A H5N1: Friend or foe? Trends Immunol 2009, 30(12):574-584.
66. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, Garc?a-Sastre A, Tolnay AE, Albrecht R, Pyles JA, Olson PH, Aicher LD, Rosenzweig ER, Murali-Krishna K, Clark EA, Kotur MS, Fornek JL, Proll S, Palermo RE, Sabourin CL, Katze MG: Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(9):3455-3460.
67. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC: Cell-mediated protection in influenza infection. Emerg Infect Dis 2006, 12:48-54. (Pubitemid 43143535)
68. Maines TR, Szretter KJ, Perrone L, Belser JA, Bright RA, Zeng H, Tumpey TM, Katz JM: Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol Rev 2008, 225:68-84.
69. Bocharov GA, Romanyukha AA: Mathematical model of antiviral immune response III. Influenza A virus infection. J. Theor. Biol. 1994, 167(4):323-360.
70. Hancioglu B, Swigon D, Clermont G: A dynamical model of human immune response to influenza A virus infection. J. Theor. Biol. 2007, 246:70-86.
71. Chang DB, Young CS: Simple scaling laws for influenza A rise time, duration, and severity. J. Theor. Biol. 2007, 246(4):621-635.
72. Tridane A, Kuang Y: Modeling the interaction of cytotoxic T lymphocytes and influenza virus infected epithelial cells. Math Biosci Eng 2010, 7:171-185.
73. Lee HY, Topham DJ, Park SY, Hollenbaugh J, Treanor J, Mosmann TR, Jin X, Ward BM, Miao H, Holden-Wiltse J, Perelson AS, Zand M, Wu H: Simulation and prediction of the adaptive immune response to influenza A virus infection. J. Virol. 2009, 83(14):7151-7165.
74. Saenz RA, Quinlivan M, Elton D, MacRae S, Blunden AS, Mumford JA, Daly JM, Disgard P, Cullinane A, Grenfell BT, McCauley JW, Wood JLN, Gog JR: Dynamics of influenza virus infection and pathology. J. Virol. 2010, 84(8):3974-3983.
75. Handel A, Longini IM, Antia R: Towards a quantitative understanding of the within-host dynamics of influenza A infections. J. R. Soc. Interface. 2010, 7(42):35-47.
76. Beauchemin C, Samuel J, Tuszynski J: A simple cellular automaton model for influenza A viral infections. J. Theor. Biol. 2005, 232(2):223-234, Draft available on arXiv:q-bio.CB/0402012.
77. Beauchemin C: Probing the effects of the well-mixed assumption on viral infection dynamics. J. Theor. Biol. 2006, 242(2):464-477, Draft available on arXiv:q-bio.CB/0505043.
78. Perelson AS, Nelson PW: Mathematical analysis of HIV-1 dynamics in vivo. SIAM Review 1999, 41:3-44. (Pubitemid 129723746)
79. Nowak MA, May RM: Virus Dynamics: Mathematical Principles of Immunology and Virology Oxford: Oxford University Press; 2000.
80. Brydon EWA, Smith H, Sweet C: Influenza A virus-induced apoptosis in bronchiolar epithelial (NCI-H292) cells limits pro-inflammatory cytokine release. J Gen Virol 2003, 84(Pt 9):2389-2400. (Pubitemid 37063128)
81. Zhirnov OP, Konakova TE, Wolff T, Klenk HD: NS1 protein of influenza A virus down-regulates apoptosis. J. Virol. 2002, 76(4):1617-1625. (Pubitemid 34094608)
82. Hornícková Z: Different progress of MDCK cell death after infection by two different influenza virus isolates. Cell Biochem Funct 1997, 15(2):87-93.
83. Stray SJ, Air GM: Apoptosis by influenza viruses correlates with efficiency of viral mRNA synthesis. Virus Res 2001, 77:3-17. (Pubitemid 32622805)
84. Price GE, Smith H, Sweet C: Differential induction of cytotoxicity and apoptosis by influenza virus strains of differing virulence. J Gen Virol 1997, 78(Pt 11):2821-2829. (Pubitemid 27480821)
85. Takizawa T, Matsukawa S, Higuchi Y, Nakamura S, Nakanishi Y, Fukuda R: Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol 1993, 74(Pt 11):2347-2355. (Pubitemid 23332295)
86. Hinshaw VS, Olsen CW, Dybdahl-Sissoko N, Evans D: Apoptosis: A mechanism of cell killing by influenza A and B viruses. J. Virol. 1994, 68(6):3667-3673. (Pubitemid 24177391)
87. Horsfall FL: On the reproduction of influenza virus; quantitative studies with procedures which enumerate infective and hemagglutinating virus particles. J. Exp. Med. 1954, 100(2):135-161.
88. Horsfall FL: Reproduction of influenza viruses; quantitative investigations with particle enumeration procedures on the dynamics of influenza A and B virus reproduction. J. Exp. Med. 1955, 102(4):441-473.
89. Hahon N, Booth JA, Eckert HL: Cell attachment and penetration by influenza virus. Infect. Immun. 1973, 7(3):341-351.
90. Choppin PW: Multiplication of two kinds of influenza A2 virus particles in monkey kidney cells. Virology 1963, 21:342-352.
91. Cairns HJF: The asynchrony of infection by influenza virus. Virology 1957, 3:1-14.
92. Henle W, Henle G, Rosenberg EB: The demonstraiont of one-step growth curves of influenza viruses through the blocking effect of irradiated virus on further infection. J. Exp. Med. 1947, 86(5):423-437.
93. Ilyushina NA, Rudneva IA, Shilov AA, Klenk HD, Kaverin NV: Postreassortment changes in a model system: HA-NA adjustment in an H3N2 avian-human reassortant influenza virus. Arch Virol 2005, 150(7):1327-1338. (Pubitemid 40837321)
94. Jaqaman K, Danuser G: Linking data to models: data regression. Nat Rev Mol Cell Biol 2006, 7(11):813-819. (Pubitemid 44627474)
95. Smith AM, Adler FR, Perelson AS: An accurate two-phase approximate solution to an acute viral infection model. J. Math. Biol. 2010, 60:711-726.
96. Miao H, Xia X, Perelson AS, Wu H: On identifiability of nonlinear ODE models and applications in viral dynamics. SIAM Rev 2011, 53(1), in print.
97. Yoshikawa T, Matsuo K, Matsuo K, Suzuki Y, Nomoto A, Tamura SI, Kurata T, Sata T: Total viral genome copies and virus-Ig complexes after infection with influenza virus in the nasal secretions of immunized mice. J. Gen. Virol. 2004, 85(Pt 8):2339-2346.
98. Ma ZM, Stone M, Piatak JMike, Schweighardt B, Haigwood NL, Montefiori D, Lifson JD, Busch MP, Miller CJ: High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J. Virol. 2009, 83(7):3288-3297.
99. Vaidya NK, Ribeiro RM, Miller CJ, Perelson AS: Viral dynamics during primary simian immunodeficiency virus infection: Effect of time-dependent virus infectivity. J. Virol. 2010, 84(9):4302-4310.
100. Blower SM, Chou T: Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004, 10(10):1111-1116.
101. Earn D, Dushoff J, Levin S: Ecology and evolution of the flu. Trends Ecol. Evol. 2002, 17(7):334-340.
102. Perelson AS: Modelling viral and immune system dynamics. Nature Rev. Immunol. 2002, 2:28-36.
103. Govorkova EA, Fang HB, Tan M, Webster RG: Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob. Agents Chemother. 2004, 48(12):4855-4863.
104. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA: Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006, 70(3):121-131. (Pubitemid 43765615)
105. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA: Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther 2007, 12(3):363-370. (Pubitemid 46787981)
106. Ilyushina NA, Hay A, Yilmaz N, Boon ACM, Webster RG, Govorkova EA: Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 2008, 52(11):3889-3897.
107. Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, Engelthaler DM, Le MH, Keim PS, Spence RP, Went GT: Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 2009, 53(10):4115-4126.
108. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD: Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother 2009, 53(5):2120-2128.
109. Smee DF, Hurst BL, Wong MH, Tarbet EB, Babu YS, Klumpp K, Morrey JD: Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010, 88(1):38-44.
110. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, Blair PJ, de Jong MD, Prichard MN, Went GT: Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5(2):e9332.
111. Brown LE, Kelso A: Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 2009, 87(4):300-308.
112. Rimmelzwaan GF, Fouchier RA, Osterhaus AD: Influenza virus-specific cytotoxic T lymphocytes: A correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 2007, 18(6):529-536.
113. Gilchrist MA, Coombs D: Evolution of virulence: Interdependence, constraints, and selection using nested models. Theor. Popul. Biol. 2006, 69(2):145-153.
114. Mideo N, Day T: On the evolution of reproductive restraint in malaria. Proc Biol Sci 2008, 275(1639):1217-1224. (Pubitemid 351481559)
115. Young D, Stark J, Kirschner D: Systems biology of persistent infection: Tuberculosis as a case study. Nat Rev Microbiol 2008, 6(7):520-528. (Pubitemid 351850976)
116. Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM: The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(34):14711-14715.
117. Steinmeyer SH, Wilke CO, Pepin KM: Methods of modelling viral disease dynamics across the within- and between-host scales: The impact of virus dose on host population immunity. Philos Trans R Soc Lond B Biol Sci 2010, 365(1548):1931-1941.
118. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH, Raman R, Cox NJ, Sasisekharan R, Katz JM, Tumpey TM: Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009, 325(5939):484-487.
119. Salomon R, Webster RG: The influenza virus enigma. Cell 2009, 136(3):402-410.
120. Coombs D, Gilchrist MA, Ball CL: Evaluating the importance of within- and between-host selection pressures on the evolution of chronic pathogens. Theor. Popul. Biol. 2007, 72(4):576-591.
121. Chen SC, Chio CP, Jou LJ, Liao CM: Viral kinetics and exhaled droplet size affect indoor transmission dynamics of influenza infection. Indoor Air 2009, 19(5):401-413.
122. Blower SM, Dowlatabadi H: Sensitivity and uncertainty analysis of complex-models of disease transmission - An HIV model, as an example. International Statistical Review 1994, 62(2):229-243.
123. Marino S, Hogue IB, Ray CJ, Kirschner DE: A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol. 2008, 254:178-196.
124. Handel A, Longini IM, Antia R: Intervention strategies for an influenza pandemic taking into account secondary bacterial infections. Epidemics 2009, 1(3):185-195.
125. Davidian M, Giltinan DM: Nonlinear Models for Repeated Measurement Data. Monographs on statistics and applied probability Chapman & Hall; 1995, 359.
126. Gelman A, Hill J: Data Analysis Using Regression and Multilevel/ Hierarchical Models Cambridge University Press; 2006.
127. Carlin BP, Louis TA: Bayesian Methods for Data Analysis. 3rd edition. Chapman & Hall/CRC; 2008.
128. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ: Time lines of infection and disease in human influenza: A review of volunteer challenge studies. Am J Epidemiol 2008, 167(7):775-785. (Pubitemid 351451744)
129. Liao CM, Yang SC, Chio CP, Chen SC: Understanding influenza virus-specific epidemiological properties by analysis of experimental human infections. Epidemiol Infect 2010, 138(6):825-835.
130. Lau LLH, Cowling BJ, Fang VJ, Chan K, Lau EHY, Lipsitch M, Cheng CKY, Houck PM, Uyeki TM, Peiris JSM, Leung GM: Viral shedding and clinical illness in naturally acquired influenza virus infections. J. Infect. Dis. 2010, 201(10):1509-1516.